Pay in 4 interest-free payments of $5.35 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Clinical trial data for FDA-approved GLP-1 receptor agonists demonstrates: Significant weight reduction: Meaningful mean body weight reduction in trial participants (see FDA-approved labeling for specific approved products) Cardiorenal protection: Reduced risk of major adverse cardiovascular events and kidney disease progression Improved lipid profiles: Decreased triglycerides and increased HDL cholesterol Blood pressure reduction: Modest but clinically significant decreases in systolic blood pressure Reduced inflammation: Decreased inflammatory markers associated with metabolic syndrome Note: Clinical outcomes cited above reflect published trial data for FDA-approved GLP-1 receptor agonists
Immediate effect of shakuyaku-kanzo-to on muscle cramp in hemodialysis patients
The findings tentatively indicate that the peptide might have contributed to a potential weight gain and a potential uptick in the overall tibial and vertebral BMC (bone mineral content) as observed via DXA, in contrast to the control set
It reduces redness and inflammation, helping to calm irritated or sensitive skin
OBAGI C-Clarifying Serum C-Clarifying Serum This antioxidant serum is formulated for normal to dry skin
